UNSPSC 51284121: Cefoperazone

This classification denotes a cephalosporin antibiotic with the molecular formula C25H27N9O8S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7U75I1278D, chemically known as 5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((((4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl)amino)(4-hydroxyphenyl)acetyl)amino)-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-(6-alpha,7-beta(r*)))- but generally known as cefoperazone, which bears US NIH Compound Identifier 44185.

UNSPSC 51284121 Cefoperazone (Commodity) does not match the work actually being solicited under this code in recent state and local opportunities. The code nominally identifies a single pharmaceutical product—cefoperazone, a third-generation cephalosporin antibiotic—yet recent opportunities tagged to it involve naloxone procurement, generic multi-source pharmaceuticals, first aid supplies for fire rescue, and direct-to-manufacturer prescription program design. None of these solicitations reference cefoperazone or narrow-spectrum antibiotic procurement. The mismatch suggests either systematic miscoding by issuing bodies or a data-tagging error in the underlying opportunity source; the code shows no relevant recent activity aligned to its stated commodity scope.

The geographic spread of the misaligned opportunities spans Florida (Seminole County), Texas (Health and Human Services Commission), and multi-state cooperative purchasing under Minnesota MMCAP with Oregon participation, with no concentration pattern. Representative recent solicitations include the Seminole County IFB for naloxone and drug deactivation systems (due July 26, 2023, with annual quantities of 1,900 units of naloxone and 800 deactivation systems), the City of Tampa IFB for medical and first aid supplies for the Fire Department Rescue Division (sealed bids due March 13, 2026, estimated contract value $700,000.00, sheltered to certified Small Local Business Enterprises with a 5 percent bid discount), and the Minnesota MMCAP RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities (responses due March 26, 2026, with July 1, 2026 contract effectiveness). Business development professionals should verify actual commodity scope and opportunity codes with issuing bodies before committing pursuit resources.